

# CITATION REPORT

List of articles citing

**A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP-458) in Healthy Adult Volunteers**

**DOI: 10.1111/cts.12947**

**Clinical and Translational Science, 2021, 14, 870-879.**

**Source:** <https://exaly.com/paper-pdf/77874701/citation-report.pdf>

**Version:** 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
12	Population Pharmacokinetic Model Development and Simulation for Recombinant Erwinia Asparaginase Produced in <i>Pseudomonas fluorescens</i> (JZP-458). <i>Clinical Pharmacology in Drug Development</i> , <b>2021</b> , 10, 1503-1513	2.3	2
11	Optimizing use of L-asparaginase-based treatment of adults with acute lymphoblastic leukemia.. <i>Blood Reviews</i> , <b>2021</b> , 100908	11.1	1
10	L-asparaginase mediated therapy in L-asparagine auxotrophic cancers: A review.. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2022</b> ,	2.2	0
9	Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences.. <i>Future Oncology</i> , <b>2022</b> ,	3.6	2
8	Novel Insights on the Use of L-Asparaginase as an Efficient and Safe Anti-Cancer Therapy.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	3
7	A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021.. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>2022</b> , 1	3.4	1
6	Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in Therapy. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , Volume 12, 55-79	2.6	0
5	SOHO State of the Art Updates and Next Questions   Asparaginase Understanding and Overcoming Toxicities in Adults with ALL. <b>2022</b> ,		1
4	Recombinant Erwinia Asparaginase (JZP458) in Acute Lymphoblastic Leukemia: Results from the Phase 2/3 AALL1931 Study.		2
3	Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management. 1-12		0
2	JZP458 closes the asparaginase allergy gap. <b>2023</b> , 141, 685-686		0
1	Population pharmacokinetics of intramuscular recombinant Erwinia chrysanthemi asparaginase ( JZP458 ) in patients with acute lymphoblastic leukemia.		0